MIF-1
A short synthetic peptide claimed to act as a myostatin antagonist — minimal published clinical or preclinical research validation.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
MIF-1 is a tetrapeptide (Tyr-Pro-Leu-Gly-NH2) marketed in grey-market peptide channels as a myostatin inhibitor. The historical literature on the Tyr-Pro-Leu-Gly sequence concerns dopamine and prolactin modulation, not myostatin biology — the myostatin-inhibitor branding is essentially marketing.
- Class
- Synthetic tetrapeptide
- Sponsor
- None
- Stage
- Preclinical / theoretical
- Marketed claim
- Myostatin inhibition
What it is
MIF-1 — sometimes written as MIF1 — refers to a tetrapeptide with the sequence Tyr-Pro-Leu-Gly-NH2, originally characterized in the academic literature in the 1970s as melanocyte-inhibiting factor and subsequently studied for effects on dopamine and prolactin signaling. The contemporary marketing of MIF-1 as a myostatin inhibitor draws on the unrelated naming overlap rather than on a published myostatin-biology research base.
Current research status
There is no contemporary pharmaceutical development program for MIF-1 as a myostatin inhibitor. The original 1970s-era research on Tyr-Pro-Leu-Gly-NH2 in dopamine/prolactin pharmacology produced limited clinical interest and did not translate into approved therapies. The repurposing of the MIF-1 designation for myostatin-inhibitor marketing in grey-market peptide channels appears to rely primarily on the labeling rather than on validated myostatin-pathway research.
Mechanistic rationale
The published mechanistic literature on Tyr-Pro-Leu-Gly-NH2 concerns interaction with dopamine D2 receptors and modulation of prolactin release. Claims that the same peptide inhibits myostatin signaling at the receptor or ligand level lack substantive published support. Anyone evaluating mechanistic claims for MIF-1 should distinguish carefully between (a) the older dopamine/prolactin literature, which is real but narrow, and (b) the contemporary myostatin-inhibitor marketing claims, which lack equivalent research support.
Available evidence
Historical literature on Tyr-Pro-Leu-Gly-NH2 (Plotnikoff et al., and subsequent work) — Limited published research on dopamine/prolactin effects in the 1970s and 1980s. None of this work concerns myostatin biology.[1]
Myostatin-inhibitor research base — No published clinical trials or rigorous preclinical studies of MIF-1 as a myostatin inhibitor.
Why it's interesting
MIF-1 is interesting almost exclusively as a case study in how peptide marketing can outrun the underlying research. The peptide is real, the historical literature is real, but the connection between the historical pharmacology and the current myostatin-inhibitor marketing is not supported by published data. For users encountering MIF-1 in grey-market peptide channels, the appropriate read is that the myostatin-inhibitor framing should be treated with substantial skepticism.
Limitations & risks
The myostatin-pathway claim base is essentially absent. Active myostatin-pathway research resides with antibody, decoy-receptor, and follistatin-related programs, not with short tetrapeptides like MIF-1. The grey-market supply chain provides no quality assurance on identity or purity. Adverse-event characterization for sustained use is essentially absent from the published literature.
Community discussion notes
MIF-1 appears in performance-enhancement community discussions, often grouped with MIF-2 and other small peptides marketed for muscle building. The community discussion frequently treats the marketed claims as if backed by substantial research — they are not.
The takeaway
MIF-1 is a case where the marketing branding outruns the published research. The historical literature on Tyr-Pro-Leu-Gly-NH2 is unrelated to myostatin biology, and the contemporary myostatin-inhibitor framing does not have a substantial research base behind it. Users interested in the myostatin-pathway mechanism should look to programs with actual evidence (apitegromab, bimagrumab) rather than to peptides whose primary support is marketing copy.
References
- Plotnikoff NP, Kastin AJ. Pharmacological studies with a tripeptide, prolyl-leucyl-glycine amide. Arch Int Pharmacodyn Ther. 1974;211(2):211-224. https://pubmed.ncbi.nlm.nih.gov/4376908/
- Lee SJ. Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction. J Clin Invest. 2021;131(9):e148372. https://pubmed.ncbi.nlm.nih.gov/33938454/